On July 29, 2024, Heart Test Laboratories, Inc., doing business as HeartSciences, released its financial results for the fiscal year ended April 30, 2024, and provided a business update. The company, which specializes in AI-powered medical technology for enhancing ECG/EKG analysis, reported no significant revenues for the fiscal year but highlighted a strong balance sheet with $5.8 million in cash and cash equivalents and $7.3 million in shareholders' equity. HeartSciences is working towards FDA submissions for its MyoVista wavECG device and MyoVista Insights cloud-platform, with the latter expected to be submitted for regulatory approval in mid-2025. The company has also secured a library of AI-ECG algorithms through licensing agreements with Mount Sinai and is expanding its intellectual property portfolio with multiple new patents. Despite facing challenges, including FDA delays, HeartSciences has made strategic advancements and is preparing for commercialization in a market projected to be worth $25 billion annually.

On July 29, 2024, Heart Test Laboratories, Inc., doing business as HeartSciences, released its financial results for the fiscal year ended April 30, 2024, and provided a business update. The company, which specializes in AI-powered medical technology for enhancing ECG/EKG analysis, reported no significant revenues for the fiscal year but highlighted a strong balance sheet with $5.8 million in cash and cash equivalents and $7.3 million in shareholders' equity. HeartSciences is working towards FDA submissions for its MyoVista wavECG device and MyoVista Insights cloud-platform, with the latter expected to be submitted for regulatory approval in mid-2025. The company has also secured a library of AI-ECG algorithms through licensing agreements with Mount Sinai and is expanding its intellectual property portfolio with multiple new patents. Despite facing challenges, including FDA delays, HeartSciences has made strategic advancements and is preparing for commercialization in a market projected to be worth $25 billion annually.